Economy/Home · Economy

[IPO Status] MBD IPO Subscription: Offer Price 7,000 Won, Minimum Deposit 70,000 Won… Listing on the 24th

Investor attention is focused on the IPO subscription of MBD, a bio-engineering convergence company. The offer price is 7,000 won, and the minimum subscription quantity is 20 shares. With a 50% subscription deposit rate applied, investors can participate with just 70,000 won. The listing date is sch

Wooil Shim
Staff Reporter
10 min read
[IPO Status] MBD IPO Subscription: Offer Price 7,000 Won, Minimum Deposit 70,000 Won… Listing on the 24th
CBC News

Investor attention is focused on the IPO subscription of MBD, a bio-engineering convergence company. The offer price is 7,000 won, and the minimum subscription quantity is 20 shares. With a 50% subscription deposit rate applied, investors can participate with just 70,000 won. The listing date is scheduled for the 24th. As the company's core business is based on precision medicine technology using organoids derived from cancer patients, market evaluation following the listing is also drawing attention.

■ Subscription Conditions… Minimum Deposit of 70,000 Won

Key points to watch in MBD's IPO subscription, taking place on the 12th, are the expected number of shares for equal allocation and the subscription deposit. Based on the offer price of 7,000 won, subscribing for the minimum quantity of 20 shares would amount to a total subscription value of 140,000 won. Applying the 50% deposit rate, the actual minimum subscription deposit required is 70,000 won.

■ What Kind of Company Is MBD?

MBD's main business is providing precision medicine and drug development support solutions that combine cancer patient-derived organoids with automated screening technology. Based on its experimental automation screening system design technology and its clinical database of cancer patients, the company is developing a next-generation precision medicine platform.

Its core technology is 'CODRP,' a cancer organoid-based diagnostic responsiveness prediction platform. Organoids are three-dimensional cell structures cultured to reproduce certain characteristics of human tissue, and cancer patient-derived organoids can be used to study tumor characteristics of individual patients or evaluate drug responses. MBD has built technology to evaluate anti-cancer drug responsiveness by combining patient-derived organoid models with its own automated screening equipment.

The CODRP platform aims to predict drug responses by linking patient clinical data with automated evaluation technology. Through this, the company is pursuing business to support patient-tailored treatment and to evaluate the responsiveness of candidate substances in the drug development process.

■ An Early Evaluation Tool in Drug Development… But With Limitations

In the anti-cancer drug development process, confirming the efficacy and safety of candidate substances requires considerable time and cost. Evaluation technology using patient-derived organoids can be used to secure additional information about drug responses in the early stages of drug development.

However, it cannot be conclusively stated that organoid experiment results fully match actual patient treatment outcomes. Clinical utility must be determined through separate validation and research results.

The competitiveness MBD emphasizes lies in the combination of its automated evaluation system and its accumulated clinical data from cancer patients. Automated screening technology supports performing multiple experiments under consistent conditions, while patient-derived organoid models are used to study the characteristics of individual tumors. Based on these technologies, the company is pursuing commercialization in the fields of precision medicine and drug development support.

■ Points to Note When Investing… Post-Listing Stock Price Determined by Demand

In IPO investment, not only technological capability and business growth potential but also actual revenue structure, profitability, research and development costs, and future funding needs should be examined together. In particular, the valuation of bio-related companies can vary depending on the progress of technology development and commercialization.

After listing, the stock price is determined by market buying and selling demand formed around the offer price. Based on the offer price of 7,000 won, if the stock price reaches four times the offer price on the first day of listing, the price would be 28,000 won. This is merely a figure calculated at the upper end of the price range permitted under regulations and does not mean the actual stock price will reach that level. Conversely, there is also a possibility that the stock price will fall below the offer price after listing.

■ What to Watch Going Forward

MBD is set to list on the 24th. The market is expected to pay close attention to the final subscription competition rate, the equal allocation results, and post-listing trading volume and stock price movements. Along with the subscription conditions of a 7,000 won offer price and a minimum subscription deposit of 70,000 won, the commercialization performance of the cancer organoid-based precision medicine platform is expected to be a key factor in evaluating the company's future value.

[Some AI assistance was used in producing this article. This does not recommend the purchase or sale of any specific stock, and investment decisions and responsibility rest with the investor.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.